IGC Pharma, Inc. Common Stock (IGC)

Seven presentations highlight patent-pending agentic automation, speech-based cognitive models, EHR mining, and predictive analytics designed to support Alzheimer's discovery and clinical development

Investors following the rapidly growing Alzheimer's disease, Artificial Intelligence (AI) , and biotechnology sectors now have an opportunity to hear directly from IGC Pharma, Inc. (NYSE American: IGC) CEO Ram Mukunda in a new interview on The Street Reports Podcast , where he discusses the Company's clinical progress, AI initiatives, and long-term strategy.

Senior management elects restricted common stock at $0.27 per share in lieu of repayment of amounts owed, including more than $552,362 of personal cash previously advanced to IGC

IGC Pharma, Inc. (NYSE: IGC), a clinical-stage biotechnology company developing Alzheimer's disease therapeutics and AI-enabled healthcare technologies, disclosed in a Form 4 filing that two senior executives increased their ownership stakes through debt-for-equity transactions.

Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) continues to build momentum as the company expands production, secures new commercial partnerships, and advances the commercialization of its graphene technology platform. Founder and CEO Craig Nicol recently appeared on CEO.CA to discuss GMG's growing ability to manufacture and sell its expanding portfolio of graphene-based products. Watch the interview Now!

As investors continue searching for the next generation of multibagger opportunities, several companies trading near or under the $1 level are capturing attention through major developments across Artificial Intelligence (AI), autonomous aviation, defense technology, digital infrastructure, battery storage, and Alzheimer's drug development.

Investors searching for the next generation of micro-cap growth stocks are increasingly focusing on companies with exposure to some of today's fastest-growing sectors, including Artificial Intelligence (AI), Alzheimer's drug development , Healthcare Technology , Defense Technology , Renewable Energy , Electric Vehicles (EVs) , Military Drones , and Digital Infrastructure .

IGC Pharma, Inc. (NYSE: IGC) a clinical-stage Biotechnology company developing treatments for Alzheimer's Disease and Artificial Intelligence (AI) enabled healthcare technologies, today announced the beta release of its proprietary Agentic Harmonization Assistant ("AHA"), a patent-pending Healthcare AI platform designed to accelerate Alzheimer's Drug Discovery, Clinical Research , Precision Medicine , and Pharmaceutical Development by helping researchers quickly combine and organize Alzheimer's disease , aging-related, and other medical data that is often scattered across multiple databases, studies, hospitals, clinical trials, healthcare systems, and research institutions.

Patent-Pending Multi-Agent Architecture Targets Fragmented Biomedical Data and Expands Toward Imaging, Omics, and Broader Health-Data Applications Ahead of Planned AAIC 2026 Demonstration in London

Featured Interviews Include Aeries Technology (NASDAQ: AERT), Virtuix Holdings (NASDAQ: VTIX), and EmpowerLit; Sponsored Programming Supported by DataVault AI (NASDAQ: DVLT), IGC Pharma (NYSE American: IGC), Medicus Pharma (NASDAQ: MDCX), and NRx Pharmaceuticals (NASDAQ: NRXP)

Brent Lucas, CEO of Envoy Medical (NASDAQ:COCH), Discusses the Company's Breakthrough Fully Implanted Hearing Device Designed to Deliver 24-Hour Hearing

IGC Pharma, Inc. (NYSE: IGC), a clinical-stage biotechnology company focused on Alzheimer’s disease, artificial intelligence , and drug discovery , is drawing renewed investor attention after Ascendiant Capital reiterated its BUY rating and increased its 12-month price target to $5.50 , citing multiple potential catalysts expected throughout 2026.

Company Continuing Limited Over-Enrollment Activities to Account for Attrition and Support Robust Modified Intent-to-Treat, End-of-Treatment and Exploratory Analyses

Kartoon Studios (NYSE: TOON) emerged as one of the market's most active after-hours movers, with shares reaching $1.45 and surging 96.74% on approximately 16.7 million shares traded following a significant legal settlement announcement on June 8, 2026.

POTOMAC, MD / ACCESS Newswire / June 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that Ascendiant Capital Markets has issued an updated equity research report on the Company, raising its price target to $5.50 per share.

American Lithium Minerals, Inc. (OTC: AMLM) continues advancing its strategy to build shareholder value across a diversified portfolio of critical minerals, precious metals , and energy transition assets after announcing a Letter of Intent (LOI) that could lead to the spinout and public listing of its 100%-owned Piscau-North Polymetallic Project in Quebec.

A growing group of sub-$1 “Mag Microcaps” is capturing investor attention as volume surges align with major catalysts across defense tech, AI infrastructure, EV innovation, alternative foods, biotech, digital media, and safety technology. Companies including Peraso Inc., Kartoon Studios Inc., OSR Holdings Inc., Triller Group Inc., Faraday Future Intelligent Electric Inc., Beyond Meat Inc., ABITS Group Inc., SOBR Safe Inc. and Datavault AI are emerging across high-volatility sectors where narrative and momentum often converge.

As investors continue searching for emerging opportunities among low-priced Nasdaq and NYSE-listed companies, several NanoCap stocks trading under $1 are gaining attention due to recent corporate developments, healthcare innovation, technology expansion, and international growth initiatives. Among the names appearing on investor radar screens are Picard Medical (NYSE: PMI), IGC Pharma (NYSE: IGC), Wellchange Holdings Company Limited (NASDAQ: WTC), WORK Medical Technology Group LTD (NASDAQ: WOK), and Semilux International Ltd. (NASDAQ: SELX).

Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis

IGC Pharma, Inc. (NYSE: IGC), a clinical-stage AI biotechnology company focused on Alzheimer’s disease, is gaining investor attention after CEO Ram Mukunda appeared on Bloomberg TV discussing the company’s lead drug candidate, IGC-AD1, a potential fast-acting therapy for agitation associated with Alzheimer’s dementia .

NEW YORK CITY, NY / ACCESS Newswire / May 30, 2026 / New to The Street announces tonight's Bloomberg Television broadcast airing at 6:30 PM ET as sponsored programming across the United States, MENA, and Latin America.

IGC Pharma, Inc. (NYSE: IGC) a clinical-stage biotechnology company developing AI-powered Alzheimer’s disease therapies, is gaining investor attention after reporting Q1 2026 financial results and continued progress in its ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer’s dementia.

Featured companies include Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holding Limited (NASDAQ:YYGH), and FreeCast (NASDAQ:AST). The show also broadcasts as sponsored programming with featured commercial segments spotlighting DataVault AI (NASDAQ:DVLT), Lantern Pharma (NASDAQ:LTRN), Roadzen (NASDAQ:RDZN), and IGC Pharma (NYSE American:IGC)

- Continued Advancement of CALMA Phase 2 Trial -

The show broadcasts as sponsored programming featuring TV commercials from IGC Pharma, Inc. (NYSE American:IGC), NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), Medicus Pharma Ltd. (NASDAQ:MDCX), and DataVault AI Inc. (NASDAQ:DVLT).